SCHEMBL19196884

SCHEMBL19196884

CCCCc1nc2c(N)nc3cc(C(=O)OC)ccc3c2n1CCCCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 9/20 1.00
TLR7 Q9NYK1 17/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19197043 0.99 TLR7 (1.00) TLR8TLR7
SCHEMBL19196816 0.97 TLR8 (1.00) TLR8TLR7
SCHEMBL19181353 0.94 TLR8 (1.00) TLR8TLR7
SCHEMBL20968311 0.93 TLR7 (1.00) TLR8TLR7
SCHEMBL20968329 0.92 TLR7 (1.00) TLR8TLR7
SCHEMBL19196891 0.91 TLR7 (0.87) TLR8TLR7
SCHEMBL19196888 0.91 TLR7 (1.00) TLR8TLR7
SCHEMBL19196817 0.91 TLR7 (0.87) TLR8TLR7
SCHEMBL14758203 0.91 TLR7 (1.00) TLR8TLR7
SCHEMBL19196889 0.90 TLR7 (1.00) TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11279701-B2 Immunomodulators and immunomodulator conjugates REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2022-03-22 US disclosed
US-20200325136-A1 IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2020-10-15 US disclosed
US-10730871-B2 Immunomodulators and immunomodulator conjugates REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2020-08-04 US disclosed
US-20190127368-A1 NLRP3 MODULATORS IFM THERAPEUTICS INC (US) 2019-05-02 US disclosed
US-20170217960-A1 IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-08-03 US disclosed
US-20170217960-A1 IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730871-B2 Immunomodulators and immunomodulator conjugates CD40, CD47, FCGRT TLR8 184/4885TLR7 124/4885
US-20190127368-A1 NLRP3 MODULATORS NLRP3, TLR7, TLR8 TLR8 3/4885TLR7 2/4885
US-11279701-B2 Immunomodulators and immunomodulator conjugates IL2, CD47, FCGRT TLR8 99/4885TLR7 44/4885
US-20170217960-A1 IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES CD47, CD40, HLA-DRB1 TLR8 150/4885TLR7 115/4885
US-20200325136-A1 IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES IL2, CD47, FCGRT TLR8 99/4885TLR7 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.